

analysis of genomic and cDNA PCR products on an ALF DNA sequencer allowed the identification of APC mutations.

Results: 125 FAP families were enrolled in our genetic analysis program. We detected APC germline mutations in 68% (85/125) of these families. These 85 families represented 123 FAP-patients and 82 individuals at risk. More than 90% (75/82) of the at-risk individuals were excluded as mutant allele carriers, causative APC germline mutations were detected in about 9% of at risk individuals. In one case mutation detection led the patient to undergo endoscopy.

Conclusions: This study demonstrates the potential of combinatorial molecular and clinical approach for genetic screening of FAP families and could serve as a general strategy for routine molecular diagnostics in a clinical laboratory. New genotype-phenotype correlations might further improve the efficacy of the molecular diagnosis of affected FAP patients.

33

ORAL

Cancer phenotype in 19 families with TP53 mutations

J.M. Birch, J.M. Varley, A.M. Kelsey. *Royal Manchester Children's Hospital & Paterson Institute for Cancer Research, UK*

Purpose: The main components of classical Li-Fraumeni cancer family syndrome (LFS) are sarcomas, breast cancer, brain tumours, adrenocortical carcinoma (ACC) and leukaemia. Germline TP53 mutations are detected in more than 50% of LFS families and in some families not strictly conforming to LFS criteria. We have investigated 40 LFS and LFS-like families to define the characteristics of cancers in carriers of TP53 mutations.

Methods: TP53 mutation status was analysed by direct sequencing of constitutional samples. In families with mutations, the distribution of cancers by age and morphology in mutation carriers was analysed.

Results: Mutations were detected in 19 families. First primary cancers in carriers included 20 sarcomas, 14 breast cancers, 9 brain tumours, 5 ACC, 2 leukaemias and 1 each of 4 other types. All except 3 cancers were diagnosed under 40 years of age. There were 7 unaffected carriers aged 9 to 50 years. Multiple primary cancers developed in 18 patients.

Conclusion: TP53 mutation phenotype closely resembles classical LFS. The age distribution of cancers is much younger than in other cancer family syndromes. Very high penetrance with greatest risk under 30 years.

34

ORAL

Inhibition of tumor growth by an antibody against a cell substrate adhesion molecule

P. Giffels, S. Köhler, Ch. DePotter¹, E. Coene¹, D. Nagel, D. Krebs, H. Schliebusch, U. Wagner. ¹*N. Goormaghtigh Inst. of Pathology, University Hospital, Ghent Dept. of Gyn. & Obst., University Bonn, S. Freud Str. 25, 53105 Bonn, Germany*

Purpose: The cell substrate adhesion molecule (defined by the MAb14C5) is typically present in high amounts on the tumour surface of in-situ and invasive breast cancer tissue. Furthermore the cell substrate adhesion receptor is involved in the metastatic process. We introduced the mAb 14C5 in an in-vivo model to prove his capacity for inhibition of invasion and metastasis.

Methods: The model uses a tumor cell line (HH16cl. 1/2, rat adenocarcinoma/fibrosarcoma), which is overexpressing the human tumor-associated antigen CA 14C5. 6 day old Sprague-Dawley rats ($n = 2 \times 12$) received tumor cells; (2×10^6) subcutaneously. After one week series Ab1 received mAb 14C5 intraperitoneally at a dosage of 100–250–500 μ g weekly ($n = 4$ per group, total group $n = 12$). A control group received polyvalent mouse IgG at the same dosage. The tumor incidence in the used model was >90%. The tumor growth was evaluated over a period of 60 days. 8 applications were administered in total.

Results: The results showed a dose dependent highly significant difference in the tumor growth as the 14C5 treated group developed a mean tumor size of 15.3 ± 18.1 mm and the control showed a mean diameter 37.2 ± 14.9 mm ($p < 0.005$ t-test).

Conclusion: In summary, the monoclonal antibody 14C5 against a human cell substrate adhesion molecule is able to inhibit tumor growth and invasion of CA14C5 overexpressing tumors in-vivo and therefore serves as a target for passive cytotoxic immunotherapy.

35

ORAL

Germline mutations in the CDKN2 and CDK4 genes are rare in melanoma families in the UK

M. Harland, J.A. Newton Bishop, E. Pinney¹, V. Bataille¹, N. Spurr, J. Cuzick¹, Peter Selby, D.T. Bishop². *ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds; ¹ICRF Maths Stats and Epidemiology, London; ²ICRF Genetic Epidemiology, Leeds, UK*

Purpose: Germline mutations in genes having a role in controlling phase G1 of the cell cycle (CDKN2 and CDK4) have been reported worldwide in melanoma families. A limited number of mutations in the CDKN2 gene have been reported in Europe (In Swedish and Italian families). We collected melanoma families in the UK with the purpose of establishing the frequency of germline mutations in the UK

Methods: Families with a history of melanoma were interviewed and examined and blood was collected for DNA extraction. All coding sequences of the CDKN2 and CDK4 genes were sequenced.

Results: 100 families were recruited to the study. From these, 14 were selected with at least 3 cases of melanoma, or 2 cases one of which had the Atypical Mole Syndrome (AMS) phenotype or multiple primaries. 5 families with 1 case of melanoma but multiple cases with the AMS were also selected. In these 19 families only one mutation in the CDKN2 gene was identified: a 24 base pair insertion in exon 1. No CDK4 mutations were identified.

Conclusion: Although there is no doubt now that germline mutations of the CDKN2 and CDK4 underlie susceptibility to melanoma in some families, the percentage of such families is low. It seems likely that other melanoma susceptibility genes remain to be identified.

36

ORAL

Allelotype of Barrett's adenocarcinoma: A search for novel tumour suppressor genes

K. Dolan, J. Garde, S.J. Walker, R. Sutton, J.K. Field. *Department of Surgery, University of Liverpool, England*

The loss of function of a tumour suppressor gene can be identified by loss of heterozygosity (LOH) studies, which were performed on 22 cases of Barrett's adenocarcinoma. All chromosomal arms were studied using 135 polymorphic markers, and eight arms demonstrated LOH in more than 40% of tumours: 3p, 5q, 9p, 11p, 13q, 17p, 17q and 18q. Further refinement of these areas of high LOH indicated that LOH on chromosomes 3p, 9p, 13q, 17p and 18q occurred at the sites of the VHL, MTS1, Rb, p53 and DCC tumour suppressor genes respectively. The refined sites on 5q, 11p and 17q are thus putative sites of novel tumour suppressor genes associated with the development of adenocarcinoma in Barrett's oesophagus. It is of note that 70% of tumours displayed LOH at the 17q11.2-q12, and we propose that this is the site of the main tumour suppressor gene associated with the development of Barrett's adenocarcinoma. These tumour suppressor genes may be useful as markers of future carcinogenesis in patients undergoing endoscopic surveillance for Barrett's oesophagus.

37

ORAL

Breast & ovarian cancer risk in BRCA mutation carriers: Implications for prevention

R. Catane¹, D. Halle¹, B. Kaufman¹, S. Eisenberg², R. Isaacson¹, N. Cherny¹, A. Lahad², G. Homreich³, U. Beller³, E. Levy-Lahad². ¹*Department of Oncology; ²Department of Medicine; ³Department of Gynecology Shaare Zedek Medical Center, Jerusalem, Israel*

Purpose: To assess the risk for breast and ovarian cancer in BRCA 1/2 mutation carriers and to suggest prevention policies.

Methods: Ashkenazi Jewish patients were analyzed for mutations common in this population: BRCA1-185delAG, 5382insC and BRCA2-6174delT.

Results: For breast cancer, mean age of onset was 38 yrs. (median 45 yrs., range 26–50, $n = 11$) and 48 yrs. (median 45 yrs., range 31–67, $n = 7$) for BRCA1 and BRCA2 respectively ($p = 0.04$). For ovarian cancer mean age of onset was 50 yrs. (median 48 yrs., range 34–72, $n = 12$) and 62 yrs. (median 59 yrs. range 42–81, $n = 9$) for BRCA1 and BRCA2 respectively ($p = 0.02$). In 6 patients with both breast and ovarian cancer (4 BRCA1 carriers, 2 BRCA2 carriers) breast cancer always preceded ovarian cancer, with onset at means of 45 yrs. and 58 yrs. respectively. Analysis of patients' families revealed a significant, twofold higher risk in BRCA1 vs. BRCA2 carriers ($p = 0.01$).